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issue-remodeling processes are largely mediated by
members of the matrix metalloproteinase (MMP)
family of endopeptidases whose expression is strictly
controlled both spatially and temporally. In this article,
we have examined the molecular mechanisms that
could contribute to modulate the expression of MMPs
like collagenase-3 and MT1-MMP during bone formation.
We have found that all-trans retinoic acid (RA), which
usually downregulates MMPs, strongly induces collagenase-3
expression in cultures of embryonic metatarsal cartilage
rudiments and in chondrocytic cells. This effect is dose and
time dependent, requires the de novo synthesis of proteins,
and is mediated by RAR-RXR heterodimers. Analysis of the
signal transduction mechanisms underlying the upregulating
effect of RA on collagenase-3 expression demonstrated that
this factor acts through a signaling pathway involving
p38 mitogen-activated protein kinase. RA treatment of
chondrocytic cells also induces the production of MT1-MMP,
T
 
a membrane-bound metalloproteinase essential for skeletal
formation, which participates in a proteolytic cascade with
collagenase-3. The production of these MMPs is concomitant
with the development of an RA-induced differentiation
program characterized by formation of a mineralized bone
matrix, downregulation of chondrocyte markers like type II
collagen, and upregulation of osteoblastic markers such as
osteocalcin. These effects are attenuated in metatarsal
rudiments in which RA induces the invasion of perichondrial
osteogenic cells from the perichondrium into the cartilage
rudiment. RA treatment also resulted in the upregulation of
Cbfa1, a transcription factor responsible for collagenase-3
and osteocalcin induction in osteoblastic cells. The dynamics
of Cbfa1, MMPs, and osteocalcin expression is consistent
with the fact that these genes could be part of a regulatory
cascade initiated by RA and leading to the induction of
Cbfa1, which in turn would upregulate the expression of
some of their target genes like collagenase-3 and osteocalcin.
 
Introduction
 
Proteolytic remodeling of extracellular matrix is an essential
event in a variety of physiological processes such as embry-
onic development, angiogenesis, reproduction, wound heal-
ing, and bone formation and remodeling (Werb, 1997). On
the other hand, abnormal breakdown of connective tissue
components contributes to a large number of pathological
conditions including rheumatoid arthritis, atherosclerosis,
and tumor invasion and metastasis (Nagase and Woessner,
1999). A large body of evidence indicates that the matrix
metalloproteinases (MMPs)* play a central role in all of
these tissue-remodeling processes. These enzymes comprise a
family of zinc-dependent endopeptidases that are collectively
capable of degrading all protein constituents of the extracel-
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lular matrix. At present, the family of human MMPs is com-
posed of more than 20 members that according to structural
and functional considerations can be classified into six
different families: collagenases, gelatinases, stromelysins,
matrilysins, membrane-type MMPs, and other MMPs (Uría
and López-Otín, 2000). Among all of these proteins, mem-
bers of the collagenase subgroup are the principal neutral
proteases with ability to degrade fibrillar collagens, generat-
ing fragments 3/4 and 1/4 the size of the original molecules,
which denature rapidly and become susceptible to further
degradation by other MMPs. To date, three human collage-
nases have been identified: fibroblast collagenase (MMP-1),
neutrophil collagenase (MMP-8), and the most recently de-
scribed collagenase-3 (MMP-13) (Freije et al., 1994).
Collagenase-3 represents a good model to study the mo-
lecular mechanisms that modulate the expression of MMPs
during normal and pathological conditions. This potent
metalloprotease is overexpressed in a growing variety of hu-
man pathological processes including malignant tumors (for
review see Balbín et al., 1999), inflammatory conditions
(Uitto et al., 1998), atherosclerosis (Sukhova et al., 1999),
aortic aneurysms (Mao et al., 1999), and destructive joint
diseases such as osteoarthritis and rheumatoid arthritis
(Lindy et al., 1997). However, in marked contrast with its
wide distribution in pathological processes collagenase-3 ex-
pression in physiological conditions has only been detected
during fetal ossification and postnatal bone remodeling
(Ståhle-Bäckdahl et al., 1997) and at lower levels in the
course of some reproductive processes (Balbín et al., 1996;
Dumin et al., 1998). Recent studies have provided informa-
tion on the mechanisms controlling collagenase-3 expression
in both normal and pathological conditions (for review see
Balbín et al., 1999). Thus, we and others have reported that
Cbfa1, a transcription factor of the 
 
runt
 
 gene family in-
volved in skeletal development, induces the expression of
collagenase-3 during bone formation (Jiménez et al., 1999;
Porte et al., 1999; Selvamurugan et al., 2000). This gene is
also strongly induced by bone-resorbing agents such as par-
athyroid hormone (PTH) and IL-6 in diverse in vitro sys-
tems including osteoblastic cell lines and mouse calvarial os-
teoblasts (Partridge et al., 1996; Kusano et al., 1998). We
have also described that collagenase-3 is expressed within fi-
broblasts adjacent to invasive breast cancer cells in response
to diffusible factors released from the epithelial tumor cells
(Uría et al., 1997). Furthermore, it has been reported that
IL-1
 
 
 
 and TNF-
 
 
 
 may induce collagenase-3 expression in
osteoarthritic cartilage (Shlopov et al., 2000), whereas sero-
tonin may be important in the upregulation of this gene
during reproductive processes (Dumin et al., 1998). How-
ever, a series of factors like PDGF, aFGF, or EGF previously
found to play important roles in upregulating expression of
other MMPs did not show any effect on collagenase-3 ex-
pression by human fibroblasts (Uría et al., 1997; 1998). By
contrast, TGF-
 
 
 
 assumed to be inhibitory for most MMPs
induces collagenase-3 expression in fibroblasts and trans-
formed keratinocytes (Uría et al., 1998; Ravanti et al.,
1999a; Johansson et al., 2000). Because these findings sug-
gested that the mechanisms regulating collagenase-3 expres-
sion could be distinct from those operating in the control of
other MMPs, we have tried to extend our search for factors
that could act as mediators of collagenase-3 expression in
normal and pathological conditions.
All-trans retinoic acid (RA) could be a good candidate to
act as an inducer of collagenase-3 expression during bone
formation or in pathological processes involving bone-form-
ing cells. In fact, retinoids have been found to play impor-
tant roles in mammalian embryonic limb development and
in bone growth and remodeling during fetal and postnatal
life (Hofman and Eichele, 1994). However, contrary to this
possibility, most previous studies have shown that RA is in-
hibitory for MMP expression (Lafyatis et al., 1990; Nichol-
son et al., 1990; Schüle et al., 1991; Schroen and Brincker-
hoff, 1996; Benbow et al., 1999). In this work, we provide
evidence that collagenase-3 and other MMPs involved in
bone formation, such as MT1-MMP (Holmbeck et al.,
1999; Zhou et al., 2000), are induced by RA and RA deriva-
tives in embryonic cartilage rudiments and chondrocytic
cells. We also analyze the morphological effects resulting
from the treatment of these cells with RA and correlate the
observed effects with altered patterns of gene expression in-
cluding those of Cbfa1, MMPs, and osteocalcin genes. Fi-
nally, we perform an analysis of the molecular mechanisms
and signaling pathways mediating collagenase-3 induction
by RA with the finding that RA acts through a signaling
pathway involving RAR-RXR heterodimers and is mediated
by p38 mitogen-activated protein kinase (MAPK). On the
basis of the transcriptional regulation studies presented
herein, together with morphological and functional observa-
tions, we propose that RA induces a regulatory cascade
involving Cbfa1 and MMPs and is coupled to the devel-
opment of a perichondrial invasion and osteogenic differen-
tiation process that occurs during endochondral ossifica-
tion.
 
Results
 
Collagenase-3 and MT1-MMP are induced by retinoic 
acid in chondrocytic cells
 
To study the putative effect of RA on the expression of colla-
genase-3 during bone formation, we first performed in situ
hybridization experiments on embryonic metatarsal rudi-
ments. As can be seen in Fig. 1, a and c, relatively low levels
of collagenase-3 transcripts were found in cartilage from
control samples. Labeling was restricted to some hyper-
trophic chondrocytes and cells localized in the perichon-
drium, but it was not detected in proliferating or in resting
chondrocytes. By contrast, a high level of collagenase-3 ex-
pression was found in rudiments treated with 10
 
 
 
7
 
 M RA
for 7 d (Fig. 1, b and d). In these samples, expression of col-
lagenase-3 was located mainly at an abnormally extended
perichondrium, being especially marked in those zones in
which it seems to invade into the underlying cartilage. In
most cases, positive signal was found in spindle-shaped cells
having oval nuclei and small size (Fig. 1 d). As in control an-
imals, chondrocytes expressing collagenase-3 were low in
number and restricted to the hypertrophic zone. The overex-
pression of collagenase-3 induced by RA was coupled to a se-
ries of morphological alterations in the metatarsal rudiments
(Fig. 1, e and f). Thus, the longitudinal growth was reduced
(control length, 3.1 
 
 
 
 0.18 mm, 
 
n
 
 
 
  
 
4; treatment with 
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10
 
 
 
8
 
 RA, 2.7 
 
 
 
 0.17 mm, 
 
n
 
 
 
  
 
4, 
 
p
 
 
 
 
 
 0.05; treatment with
10
 
 
 
7
 
 RA, 2.2 
 
 
 
 0.14 mm,
 
 n
 
 
 
  
 
4, 
 
p
 
 
 
 
 
 0.01). Histologically,
the RA-treated metatarsal rudiments showed a decrease in
the degree of structural anisotropy. As a result, boundaries
between resting and proliferating zones appeared poorly de-
fined and could hardly be recognized in these samples (Fig.
1 f). Likewise, RA treatment resulted in a partial inhibition
of cellular enlargement during chondrocytic hypertrophy. In
this way, hypertrophic-like chondrocytes showing mitotic
figures were sometimes observed in RA-treated cartilages.
Additionally, the perichondrium in RA-treated cultures ap-
peared bigger and more irregular than in controls. Whereas
the perichondrium in controls was only two to three layers
thick (Fig. 1 e), the perichondrium in RA-treated cultures
contained five to nine layers of cells, often invading into the
underlying cartilage (Fig. 1 f). Proteoglycan content, as esti-
mated by cytochemical staining with Alcian blue, was lower
in RA-treated cartilages. This effect was especially evident in
zones where the perichondrium expands and gives rise to
cup-shaped depressions protruding into cartilage. An abrupt
transition was evident between the weakly Alcian blue–
stained intrachondral cells invading from the perichondrium
and the strongly stained surrounding chondrocytes (Fig. 1
g). Such intrachondral cells were larger in size than surface
perichondrial cells, presented basophilic cytoplasm (Fig. 1
h), and were histochemically positive for calcification (un-
published data). The characteristics of perichondrium-
derived cells in RA-treated rudiments partially resembled
those of osteoblasts and clearly differed from those of un-
treated bones where a sequential differentiation process from
perichondrial cells to chondrocytes was observed.
To further study the effect of RA on the expression of col-
lagenase-3, we first used primary chondrocyte cultures. Cells
were treated with 10
 
 
 
6
 
 M RA, and total RNA was obtained
at different times and analyzed by Northern blot using a spe-
cific collagenase-3 probe. As shown in Fig. 2 a, RA induced
the accumulation of a 2.9-kb mRNA transcript correspond-
ing to collagenase-3, the maximal effect being reached
Figure 1. Collagenase-3 expression in 
metatarsal bone rudiments. Paraffin 
sections from embryonic metatarsal 
rudiments untreated (a and c) or treated 
with RA (b and d) were hybridized with 
a labeled antisense riboprobe for 
collagenase-3. In untreated cultures, 
collagenase-3 expression was relatively 
low, being restricted to a low number of 
cells located mainly in the perichondrium. 
(c) Higher magnification of a peripheric 
area showing that most collagenase-3–
positive cells were small sized and flat 
shaped. Metatarsals treated with RA (b) 
showed higher levels of collagenase-3 
expression. Positive signal was increased 
in zones in which the perichondrium 
invaded into the underlying cartilage (d). 
(e–h) Metatarsal sections untreated (e) 
and treated with RA (f–h) and stained 
with toluidine blue (e, f, and h) and 
Alcian blue (g). A clear boundary
between proliferating and hypertrophic 
zones was observed in untreated meta-
tarsals (e). RA-treated cultures showed a 
partial inhibition of cellular enlargement 
during chondrocytic hypertrophy result-
ing in ill-defined boundaries between 
proliferating and hypertrophic zones (f). 
Invasion of cartilage by cells from the 
perichondrium also increased in 
RA-treated cultures (f, arrowhead; g 
and h). Weakly Alcian blue–stained 
intrachondral cells invading from the 
perichondrium are observed in g. (h) 
Higher magnification of intrachondral 
cells showed in g and stained with 
toluidine blue. These cells are elongated 
and have basophilic cytoplasm. Bars: 
(a, e, and f) 100  m; (b) 160  m; (c, d, 
and g) 40  m; (h) 25  m. 
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between 24 and 48 h and declining at longer times of incu-
bation. Similar results were obtained when rat chondrosar-
coma (RCS) cells were used as the experimental model. The
main advantage of using this cell line derives from the fact
that its chondrocyte phenotype is extremely stable in stan-
dard tissue culture conditions compared with the unstable
phenotype exhibited by other cells from the same lineage
(Mukhopadhyay et al., 1995). RCS cells treated with
10
 
 
 
6
 
 M RA also showed a marked induction of collagenase-3
expression (Fig. 2 b). In addition, a dose–response analysis
showed that as little as 10
 
 
 
7
 
 M RA induced a detectable ex-
pression of collagenase-3 mRNA, whereas incubation of the
cells with 10
 
 
 
5
 
 M induced a maximal accumulation of this
mRNA (unpublished data). To determine if the inducing ef-
fect of RA on collagenase-3 mRNA levels was also reflected
at the protein level, we performed Western blot analysis with
conditioned medium from RCS cells treated with RA. As
can be seen in Fig. 2 c, a band immunoreactive against colla-
genase-3 monoclonal antibodies was detected in medium
from cells treated with 10
 
 
 
6
 
 M RA for 48 h. This band was
absent in medium obtained from control untreated cells. A
time course analysis demonstrated that the maximum level
of collagenase-3 protein was detected in cells treated with
RA for 72 h (Fig. 2 c).
We next examined the possibility that other MMPs could
also be a target of the upregulatory effect of RA in chon-
drocytic cells. We focused our interest on MT1-MMP, a
membrane metalloproteinase essential for bone formation
(Holmbeck et al., 1999; Zhou et al., 2000) and proposed to
be part of a proteolytic cascade involving collagenase-3
(Knäuper et al., 1996). As illustrated in Fig. 2, a and b,
MT1-MMP expression was increased by RA treatment both
in RCS cells and primary chondrocyte cultures, although in
these cells the upregulatory effect was lower. Further studies
also revealed that other MMPs, such as gelatinase B (MMP-9)
potentially involved in bone formation, are not significantly
upregulated by retinoids in chondrocytic cells (unpublished
data).
 
Collagenase-3 induction by retinoic acid is coupled 
to an osteogenic differentiation process mediated 
by Cbfa1
 
After treatment of cell cultures with RA, a clear time-depen-
dent change in cell morphology was found. Both primary
chondrocytes and RCS cells shifted from rounded polygonal
shape to a very distinct flattened and more stellate shape, be-
ing such changes correlated with a decrease of proteoglycan
content (unpublished data). In addition, an increase in cal-
cium deposition was observed in RCS cells and primary cul-
tures of chondrocytes. Previous studies have provided op-
posing results on the role that RA exerts on chondrocytic
differentiation. Some works have shown that RA induces
maturation and mineralization of chondrocytes (Iwamoto et
al., 1994; Cancedda et al., 1995; Koyama et al., 1999),
whereas other groups have reported that RA exerts an inhib-
itory effect on chondrocyte function (Ballock et al., 1994;
De Luca et al., 2000). To analyze the molecular alterations
associated with these morphological changes, we examined
the putative occurrence of variations in the expression levels
of different genes that could be associated with chondrocytic
differentiation. Northern blot analysis revealed that type II
collagen expression was strikingly downregulated after RA
treatment of primary chondrocytes and RCS cells (Fig. 2, d
and e). The loss of this cartilage-specific collagen suggested
that chondrocytic cells had differentiated toward a mature
hypertrophic chondrocyte or, alternatively, had dedifferenti-
ated toward a fibroblastic phenotype. Hybridization of the
blots with a probe for type X collagen showed the absence of
detectable mRNA transcripts of this gene whose expression
is characteristic of hypertrophic chondrocytes. However, hy-
bridization of the same blots with probes for osteoblastic
Figure 2. Effect of RA on expression of 
collagenase-3 and different chondro-
cytic and osteoblastic markers. (a) Pri-
mary chondrocytes were exposed to 
10
 6 M RA for the times shown, and 
then total RNA was extracted and ana-
lyzed by Northern blot with collage-
nase-3 and MT1-MMP cDNA probes. 
28S rRNA stained with ethidium bro-
mide is shown as loading control. (b) 
RCS cells were 
incubated with 10
 6 M RA for the times 
shown, and total RNA was then 
analyzed as in a. (c) RCS cells were 
treated with 10
 6 RA for the times 
indicated, and proteins in conditioned 
media were analyzed by Western blot 
using an antibody against collagenase-3. 
Cells were also treated for 72 h with 
different RA concentrations, and 
collagenase-3 protein secreted to media 
was detected. Primary chondrocytes (d) 
or RCS cells (e) were induced with
10
 6 M RA for the times shown, and to-
tal RNA was analyzed by Northern blot 
with specific probes for the indicated  
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markers provided positive results. Thus, type I collagen pos-
itive signal was observed in RA-treated primary chondro-
cytes (Fig. 2 d). Similarly, osteocalcin mRNA was markedly
induced in RA-treated RCS cells (Fig. 2 e), although the ef-
fect on primary cultures was virtually undetectable (unpub-
lished data). These differences in the expression patterns of
both types of RA-treated cells indicate that their response to
retinoids is not identical, although they share several com-
mon RA-induced morphological and molecular alterations
suggestive of their differentiation toward osteoblastic-like
cells. In relation to this, it is remarkable the finding that ma-
trix molecules, including osteocalcin, are only expressed in
some populations of morphologically indistinguishable os-
teoblasts depending on variations in maturational status or
in the microenvironment in which they are present (Cande-
liere et al., 2001). Consistent with this, in situ hybridization
experiments on metatarsal rudiments revealed that osteocal-
cin transcripts were detected clearly in some cells from rudi-
ments treated with 10
 
 
 
7
 
 M RA for 7 d (Fig. 3 a) but not in
control samples. In these RA-treated rudiments, expression
of osteocalcin significantly overlapped that of collagenase-3,
being found in a relatively low number of small spindle-
shaped cells located in zones where the perichondrium ap-
peared to protrude into the underlying cartilage (Fig. 3 a).
Osteocalcin expression was negatively correlated with pro-
teoglycan content (Fig. 3 b).
We next tried to evaluate the possibility that the effect of
RA could be mediated by protein factors involved in bone
cells maturation. In this regard, it is remarkable that Cbfa1,
a transcription factor involved in the maturation of chon-
drocytes and osteoblasts, is an in vivo inducer of both osteo-
calcin and collagenase-3 expression in bone cells (Ducy et
al., 1997; Jiménez et al., 1999; Porte et al., 1999; Selvamu-
rugan et al., 2000). From these considerations, we examined
the possibility that RA could modulate Cbfa1 levels in RCS
cells and primary cultures of chondrocytes. Interestingly,
and as shown in Fig. 2, d and e, Northern blot analysis con-
firmed that RA induced the expression of this transcription
factor. Cbfa1 induction was detected at 24 h of RA treat-
ment, thus preceding the appearance of collagenase-3 tran-
scripts. Cbfa1 transcripts overlapping with those of col-
lagenase-3 were also increased in RA-treated metatarsal
rudiments (Fig. 3, c and d).
To further support the possibility that the effect of RA on
collagenase-3 expression was mediated by Cbfa1, we per-
formed metatarsal organ cultures from embryos with tar-
geted deletion of the Cbfa1 gene. A comparative morpho-
logical analysis with control littermate metatarsal rudiments
revealed that Cbfa1-null rudiments were shorter in both to-
tal length (3.0 
 
 
 
 0.11 mm, 
 
n 
 
  
 
4 versus 3.7 
 
 
 
 0.14 mm,
 
n 
 
 
 
 5, 
 
p
 
 
 
 
 
 0.01) and fraction of hypertrophic cartilage. RA
treatment of rudiments from Cbfa1
 
 
 
/
 
 
 
 mice resulted in a
Figure 3. Osteocalcin and Cbfa1 expression in metatarsal bone rudiments treated with RA. Osteocalcin mRNA was found in RA-treated 
rudiments in a low number of cells located in zones in which perichondrium appeared extended into the underlying cartilage (a). Cells 
showing positive signal (arrowhead) were small sized and spindle shaped and partially overlapped those positive for collagenase-3. 
Osteocalcin expression was correlated with a decrease of proteoglycans as demonstrated by cytochemical detection with Alcian blue on 
paraffin sections (b, arrowhead). Cbfa1 expression was observed in both untreated rudiments (c) and treated with RA (d). In untreated 
cultures, Cbfa1 expression was low, being restricted to cells of the perichondrium (arrowhead) and some hypertrophic chondrocytes 
(asterisk). By contrast, metatarsals treated with RA (d) showed higher levels of Cbfa1 expression that partially overlapped that of collagenase-3. 
Positive signal was especially evident in central (diaphyseal) zones in which the perichondrium was expanded and typical chondrocytes 
were scarce (arrowhead). Bars: (a and b) 250  m; (c and d) 67  m. 
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slight decrease of longitudinal growth (2.7 
 
 
 
 0.12 mm, 
 
n 
 
 
 
4 versus 3.0 
 
 
 
 0.11 mm, 
 
n
 
 
 
  
 
4, 
 
p
 
 
 
 
 
 0.01) that was propor-
tionally lower than that observed in RA-treated Cbfa1
 
 
 
/
 
 
 
rudiments (2.8 
 
 
 
 0.14 mm, 
 
n
 
 
 
 
 
 5 versus 3.7 
 
 
 
 0.14 mm,
 
n
 
 
 
 
 
 5, 
 
p
 
 
 
 
 
 0.01). RA treatment of Cbfa1
 
 
 
/
 
 
 
 rudiments also
resulted in a marked inhibition of chondrocytic hypertrophy
(Fig. 4, a and c), a result similar to that observed in wild-
type samples (Fig. 1). However, RA treatment did not in-
duce any increase of perichondrial thickness in Cbfa1-null
metatarsal rudiments, a result different from that observed
in the wild-type samples. In situ hybridization studies
showed that collagenase-3 expression was absent in both un-
treated and RA-treated Cbfa1
 
 
 
/
 
 
 
 metatarsal bone rudiments
(Fig. 4, b and d), which agrees with the proposal that Cbfa1
is required for the RA-induced increase of collagenase-3 ex-
pression. We next examined the possibility that the effect of
RA on collagenase-3 expression could be influenced by the
absence of MT1-MMP, which as mentioned above is in-
volved in both bone formation and collagenase-3 activation.
To this end, we used metatarsal cultures from MT1-MMP–
null embryos and analyzed the effects of RA on these ex-
plants. Similar to the case of Cbfa1-null rudiments, MT1-
MMP
 
 
 
/
 
 
 
 rudiments were shorter than wild-type littermate
samples (2.8 
 
 
 
 0.13 mm, 
 
n
 
 
 
  
 
6, versus 3.5 
 
 
 
 0.16 mm,
 
n
 
 
 
  
 
4, 
 
p
 
 
 
 
 
 0.01) and showed a clear histological alteration
at the hypertrophic zone where chondrocytes were smaller in
size and appeared highly disorganized (Fig. 4 e). RA treat-
ment of MT1-MMP
 
 
 
/
 
 
 
 rudiments induced a significant de-
crease in length (2.1 
 
 
 
 0.18 mm, 
 
n
 
 
 
  
 
6 versus 2.8 
 
 
 
 0.13
mm, 
 
n
 
 
 
  
 
6, 
 
p
 
 
 
 
 
 0.01), which was comparable to that ob-
served in wild-type rudiments (2.9   0.13 mm, n   4 ver-
sus 3.5   0.16 mm, n   4, p   0.01). The observed cyto-
logical alterations in untreated MT1-MMP
 /  samples were
also enhanced in RA-treated rudiments (Fig. 4 g). In situ hy-
bridization studies showed positive collagenase-3 expression
in both untreated and RA-treated MT1-MMP
 /  metatarsi
(Figs. 4, f and h). In untreated rudiments, labeling was re-
stricted to some hypertrophic chondrocytes and cells of the
perichondrium, a pattern similar to that observed in samples
from control mice (Fig. 4 f). Likewise, RA-treatment of
MT1-MMP
 /  rudiments resulted in an increased expres-
sion of collagenase-3. However, in these mutant bone rudi-
ments collagenase-3 expression was found mainly at the dis-
organized hypertrophic chondrocytes located at the middle
of the bone (Fig. 4 h). Like in Cbfa1
 /  metatarsi, RA treat-
ment did not induce any perichondrial expansion in MT1-
Figure 4. Collagenase-3 expression in 
metatarsal bone rudiments from em-
bryos with targeted deletion of the 
Cbfa1 and MT1-MMP genes. Cbfa1-null 
(a–d) and MT1-MMP–null (e–h) metatarsal 
rudiments were untreated (a, b, e, and f) 
or treated with RA (c, d, g, and h) and 
stained with Alcian blue and nuclear fast 
red (a, c, e, and g) or hybridized with a 
labeled antisense riboprobe for collage-
nase-3 (b, d, f, and h). Untreated Cbfa1
 /  
rudiments showed signs of cellular 
disorganization, especially in the hyper-
trophic zone where a clear Alcian blue 
staining was observed (a). Treatment of 
Cbfa1
 /  metatarsi with RA resulted in a 
marked inhibition of the chondrocytic 
hypertrophy (c). In situ hybridization 
studies failed to find positive signal for 
collagenase-3 in either untreated (b) or 
RA-treated (d) rudiments. Untreated 
MT1-MMP
 /  rudiments showed a 
disorganized hypertrophic zone with 
an intense Alcian blue staining (e). 
Collagenase-3 expression was low but 
could be observed in cells located 
mainly in the perichondrium (f). 
Treatment of MT1-MMP
 /  metatarsi 
with RA induced some cytological 
changes (g) and resulted in an increased 
collagenase-3 expression (h) at the 
hypertrophic chondrocytes. Bars, 
200  m.Regulation of Cbfa1 and MMPs by retinoic acid | Jiménez et al. 1339
MMP
 /  rudiments. According to these results, we con-
clude that the RA-induced increase of collagenase-3 expres-
sion was not dependent of MT1-MMP.
Induction of collagenase-3 expression in chondrocytic 
cells is mediated by RAR-RXR heterodimers and 
involves the p38 MAPK pathway
The above observation that all-trans RA upregulated collage-
nase-3 expression in chondrocytic cells prompted us to ex-
amine the nature of the nuclear retinoic acid receptors pre-
sumably involved in this process. To this purpose, we first
analyzed by Northern blot the expression levels of the differ-
ent retinoid receptors in RCS cells (Fig. 5). This analysis re-
vealed that RAR  and RAR  receptors are constitutively ex-
pressed but show some variations after RA treatment,
indicating that both of them could be involved in the pro-
cess. We next evaluated the effect of different agonistic and
antagonistic retinoids on collagenase-3 expression in these
cells. As shown in Fig. 6 a, the RAR -selective agonist
Ro40-6055 induced a collagenase-3 expression similar to
that observed with all-trans RA. In addition, when cells were
incubated with the RAR -selective (Ro48-2249) or the
RAR -selective (R044-4753) retinoids, collagenase-3 ex-
pression was also induced, although the upregulatory effect
was much lower than that observed after treatment with
RAR  agonists. Furthermore, the RAR -selective antago-
nist Ro41-5253 extensively blocked the RA-induced accu-
mulation of collagenase-3, whereas the RAR -selective an-
tagonist LE135 only showed a slight inhibitory effect (Fig. 6
b). Finally, we examined the possibility that RXR-mediated
signaling pathways could also contribute to the observed up-
regulation of collagenase-3 expression by retinoids. Thus,
RCS cells were incubated with different RAR agonists in
the presence or absence of the RXR-selective retinoid
LG100064, and collagenase-3 levels were analyzed by
Northern blot. As shown in Fig. 6 a, the presence of this
RXR-selective retinoid produced a significant increase in the
collagenase-3 mRNA levels when compared with values ob-
tained after incubation with RAR agonists alone. Taken to-
gether, these results indicate that RAR-RXR heterodimers,
likely containing RAR  isoforms, are involved in the trans-
duction of the retinoid signal that leads to the induction of
collagenase-3 in chondrocytic cells.
To provide further insights into the mechanisms underly-
ing the upregulating effect of RA on collagenase-3 expres-
sion in chondrocytic cells, we performed cell culture experi-
ments in the presence of the protein synthesis inhibitor
cycloheximide. As shown in Fig. 7 a, incubation of RCS
cells with cycloheximide blocked the effect of RA on collage-
nase-3 mRNA levels. Therefore, we conclude that de novo
protein synthesis is required for collagenase-3 induction by
RA. We next evaluated the possibility that different signal-
ing pathways could be involved in this process. To this pur-
pose, RCS cells were first incubated with RA in the presence
or absence of several inhibitors of these signaling pathways,
and the levels of collagenase-3 were examined by Northern
blot. As illustrated in Fig. 7 b, the highly specific PKC in-
hibitor GF109203X diminished the upregulating effect of
RA on collagenase-3 expression, indicating the involvement
of a PKC in this process. However, the classical but less spe-
cific PKC inhibitor staurosporine not only was unable to di-
minish its expression but even enhanced it, likely through an
alternative mechanism (Shoshan and Linder, 1994). To de-
termine whether a tyrosine kinase was also involved in colla-
genase-3 induction, RCS cells were incubated with RA in
the presence or absence of genistein. As shown in Fig. 7 b,
this inhibitor blocked the induction of collagenase-3 expres-
sion elicited by RA. By contrast, incubation of RCS cells
with H89, a protein kinase A inhibitor, or with indometha-
cin, which blocks prostaglandin synthesis, did not diminish
RA-mediated induction of collagenase-3 and even promoted
it (Fig. 7 b). Taken together, these results indicate that the
positive effect of RA on collagenase-3 expression in RCS
cells is exerted through a signaling pathway involving PKC
and tyrosine kinase activities.
On the other hand, it is well established that activation of
tyrosine kinase-dependent signaling can activate down-
stream signaling cascades including MAPKs. To elucidate
the putative implication of extracellular signal–regulated ki-
nase (ERK)1,2, Jun NH2-terminal kinase (JNK)1, and p38
Figure 5. Expression of RA receptors in RCS cells. Cells were 
induced with 10
 6 M RA for the times indicated, and total RNA was 
analyzed by Northern blot with specific probes for  RAR and  RAR.
Figure 6. Effect of different RA receptors agonists 
and antagonists on collagenase-3 expression. RCS 
cells were cultured for 48 h in the presence of 10
 6 M 
of different agonists (Ro40-6055,  RAR agonist; Ro48-
2249,  RAR agonist; Ro44-4753,  RAR agonist; RXR 
agonist, LG100064) (a) or with 10
 6 M RA plus different 
antagonists (Ro41-5253,  RAR antagonist; LE135, 
 RAR antagonist) (b). Total RNA was extracted, 
and collagenase-3 transcripts were detected by 
Northern blot.1340 The Journal of Cell Biology | Volume 155, Number 7, 2001
MAPKs pathways in mediating the RA-dependent induc-
tion of collagenase-3 expression in RCS cells, we studied the
activation of these different kinases after RA treatment. As
illustrated in Fig. 8 a, only p38 showed constitutive levels of
activation and was appreciably activated after a 90-min RA
treatment. This effect continued for at least 12 h. To test the
implication of p38 in RA-elicited collagenase-3 induction,
we pretreated RCS cells with the p38 inhibitor SB 203580
and then analyzed the obtained RNA after incubation with
RA. As shown in Fig. 8 b, treatment of these cells with SB
203580 abolished the RA-induced expression of collagenase-3.
In contrast, the ERK1,2 pathway inhibitor PD 98059
strongly augmented collagenase-3 induction by RA in RCS
cells. It is remarkable that PD 98059 alone, in the absence of
RA, did not elicit any inductive effect on collagenase-3 ex-
pression. We also examined if the actions of these MAPK in-
hibitors could be extended to other RA-induced genes such
as Cbfa1 and osteocalcin. As shown in Fig. 8 b, the p38 in-
hibitor SB 203580 abolished the RA-induced expression of
Cbfa1 and osteocalcin, whereas PD 98059 increased the
RA-mediated induction of both genes. These results provide
evidence that the p38 MAPK signaling pathway seems es-
sential for expression of the different genes induced by RA in
chondrocytic cells, whereas ERK1,2 MAPKs play an inhibi-
tory role on the process.
Discussion
Skeletal formation and remodeling are strictly regulated both
temporally and spatially by a variety of molecules. Among
these regulatory factors, retinoids have raised large interest
due to their pleiotropic and profound effects in several events
occurring during bone formation. Thus, RA has been impli-
cated in limb bud development, anterior/posterior axis orien-
tation, chondrogenesis, growth plate maturation, chondro-
cyte apoptosis, and matrix mineralization (Hofman and
Eichele, 1994). This wide variety of RA functional roles has
made difficult to identify the effector molecules involved in
these different processes and to elucidate the molecular mech-
anisms underlying each of them. In this work, we provide ev-
idence that collagenase-3, a potent proteolytic enzyme associ-
ated with tumor and arthritic processes but whose expression
in normal tissues is essentially restricted to bone formation, is
induced by RA in chondrocytes during endochondral ossifi-
cation. Likewise, MT1-MMP, a membrane-bound protease
whose relevance in skeletal formation has been uncovered re-
cently (Holmbeck et al., 1999; Zhou et al., 2000), is also in-
duced by RA in chondrocytic cells. Interestingly, the produc-
tion of these MMPs is concomitant with the development of
an RA-induced osteogenic differentiation program mediated
by Cbfa1. Finally, we demonstrate that these effects require
the participation of a signaling pathway involving the activity
of p38 MAPK.
According to in situ hybridization, Northern blot, and
Western blot analysis, RA is a potent inducer of collage-
Figure 7. Analysis of the signaling pathways involved in 
RA-mediated induction of collagenase-3 expression. (a) Effect of 
cycloheximide (CHX) (0.5  g/ml) on collagenase-3 mRNA levels 
induced in RCS cells treated with 10
 6 M RA for 48 h. (b) Effect 
of inhibitors of different intracellular signaling pathways on 
RA-induced collagenase-3 mRNA levels in RCS cells. Genistein 
(100  g/ml), staurosporine (2 nM), GF109203X (5  M), H89 (500 
nM), and indomethacin (5  M) were added to the culture medium
1 h before induction with 10
 6 M RA. Total RNA was extracted after 
48 h and analyzed by Northern blot with a collagenase-3 probe.
Figure 8. Implication of p38 MAPK in collagenase-3 induction 
by RA. (a) RCS cells were treated with 10
 6 M RA for the times 
indicated. Cells were lysed, and protein extracts were analyzed by 
Western blot. The levels of activated ERK1/2, JNK1/2, and p38 were 
determined using phosphospecific antibodies for the corresponding 
MAPKs (p-ERK1/2, p-JNK1/2, p-p38). As controls, levels of total 
ERK1/2 and p38 were determined with specific antibodies. Cell 
lysates from HaCaT cells treated for 20 min with 10
 7 M TPA or 20 
ng/ml TNF-  were used as positive controls for activated ERK1/2 or 
JNK1/2 and p38, respectively. (b) Increasing amounts of p38 inhibi-
tor SB 203580 or ERK1/2 inhibitor PD 98059 ( g/ l) were added to 
the culture medium 1 h before inducing RCS cells with 10
 6 M RA. 
Total RNA was extracted, and collagenase-3 transcripts were 
detected by Northern blot. The same filter was subsequently hybrid-
ized with probes specific for Cbfa1 and osteocalcin.Regulation of Cbfa1 and MMPs by retinoic acid | Jiménez et al. 1341
nase-3 expression in cartilage rudiment cultures, primary
chondrocyte cultures, and chondrosarcoma cells. This effect
is time and dose dependent, requires protein synthesis, and
is mediated by RAR-RXR heterodimers, likely involving
RAR  isoforms. The finding of an upregulatory effect of RA
on the production of proteolytic enzymes like MT1-MMP
and collagenase-3 confirms and extends previous observa-
tions indicating that different MMPs can be induced by ret-
inoids in human, murine, and avian cells (Ballock et al.,
1994; Connolly et al., 1994;Varghese et al., 1994; Guérin et
al., 1997; Nie et al., 1998). However, these findings are in
clear contrast with many studies demonstrating that reti-
noids are repressors of MMP expression (Lafyatis et al., 1990;
Nicholson et al., 1990; Schüle et al., 1991; Schroen and
Brinckerhoff, 1996; Benbow et al., 1999). These RA-
induced inhibitory mechanisms have been proposed to be
mediated mainly through interaction of RAR-RXR het-
erodimers with AP-1 transcription factors, which bind to the
AP-1 site present in the promoter region of most MMP
genes. Therefore, it is paradoxical that the collagenase-3
gene, which contains a functional AP-1 site (Pendás et al.,
1997), is not repressed by RA. Some studies have reported
that AP-1 sites may also mediate RA stimulatory effects (De-
sai and Niles, 1997); however, we have been unable to find
any indication of the involvement of the AP-1 site in the
RA-induced expression of the collagenase-3 gene as assessed
by lack of JNK activation, induction of fos or jun genes, aug-
mented translocation of these factors to the nucleus, or en-
hanced binding to the AP-1 element (unpublished data).
These results indicate that sequences other than AP-1 influ-
ence the responsiveness of the collagenase-3 gene to RA.
Therefore, we can conclude that regulation of MMP gene
expression by retinoids is complex and markedly dependent
on cell type or on available factors mediating RA effects in
different normal or pathological conditions.
Previous works have reported conflicting results regarding
the role of retinoids in the process of chondrocyte matura-
tion. Thus, several studies have proposed a central role for
RA in skeletal development, promoting chondrocyte termi-
nal maturation and matrix mineralization (Iwamoto et al.,
1994; Cancedda et al., 1995; Koyama et al., 1999). By con-
trast, other groups have reported that RA negatively regu-
lates bone growth by inhibiting chondrocyte maturation and
bone matrix synthesis (Ballock et al., 1994; De Luca et al.,
2000). Our results derived from morphological studies and
gene expression analysis using murine cartilage rudiments
and chondrocytic cells support the possibility that RA is a
signaling molecule that in cell cultures promotes an osteo-
genic differentiation program. This effect is attenuated in
metatarsal rudiments in which RA induces the invasion of
perichondrial osteogenic cells from the perichondrium into
the cartilage rudiment. Consistent with previous studies
(Ballock et al., 1994), RA treatment of murine chondrocytic
cells induced morphological changes, resulting in more elon-
gated and flattened cells with stellate-like shape resembling
osteoblasts. Furthermore, the coordinated expression of
markers such as Cbfa1, osteocalcin, MT1-MMP, and col-
lagenase-3 may reflect defined stages of this differentia-
tion process. Interestingly, RA-treatment of metatarsi from
MT1-MMP
 /  mice induced collagenase-3 expression in
hypertrophic-like chondrocytes but did not lead to forma-
tion of collagenase-3–positive cells with osteoblastic charac-
teristics, suggesting that the presence of both proteases is
needed for the development of this osteogenic differentia-
tion process. Finally, the observation that RA induces the
formation of a mineralized bone matrix also suggests that
chondrocytes have acquired some functional capabilities
necessary to act as osteoblast-like cells. Nevertheless, we
must consider the possibility that the addition of relatively
high concentrations of RA may lead to a series of phenotypic
changes that do not reflect a true osteogenic differentiation
of hypertrophic chondrocytes. However, it is remarkable
that concentrations as low as 10
 8 M RA, which fall within
physiological levels (Gentili et al., 1993), still have an upreg-
ulatory effect on MMP expression in metatarsal rudiments.
Therefore, it is tempting to speculate that endogenous reti-
noids may trigger the regulatory cascade described in this
work, leading to induction of MT1-MMP and collagenase-3
that in turn may play a direct role in replacement of cartilage
by bone during development.
The induction of MMPs by RA is a transient event. The
lag between the initiation of treatment and the expression
of MMPs together with the observation that the effect of
RA on collagenase-3 production is dependent of de novo
synthesis of proteins indicate that the induction of an in-
termediate factor may be involved in this process. An inter-
esting possibility is that Cbfa1, a key regulator of osteo-
blast differentiation and function (Karsenty, 1999), may
act as this intermediate factor. Several experimental find-
ings provide support to this proposal. Thus, we have
shown that Cbfa1 expression in RCS cells is also strongly
upregulated by RA in a time-dependent manner. We have
also found that Cbfa1 is necessary for collagenase-3 expres-
sion as assessed by the lack of expression of this gene in
both untreated and RA-treated metatarsal rudiments ob-
tained from Cbfa1-null mice. Furthermore, recent in vivo
and in vitro studies have demonstrated that Cbfa1 is essen-
tial for controlling transcriptional activation of genes en-
coding osteoblastic proteins through binding to Cbfa func-
tional elements present in these genes (Ducy et al., 1997;
Jiménez et al., 1999). Finally, we have also observed the
presence of putative Cbfa elements in the MT1-MMP pro-
moter, which is also induced by RA in these cells (Fig. 2;
unpublished data). Assuming that this differentiation pro-
cess triggered by RA is mediated by Cbfa1 and leads to the
induction of MMPs, we can speculate about the potential
role of these proteolytic enzymes during bone develop-
ment. Thus, the wide substrate specificity of collagenase-3
could facilitate the degradation of different matrix compo-
nents of the bone anlagen in order to initiate the formation
of mature bone. In addition, collagenase-3 in collaboration
with other MMPs (Engsig et al., 2000) may regulate the
availability of bone growth factors sequestered as inactive
molecules in the matrix or blocked by interaction with
their binding proteins. Finally, collagenase-3 could facili-
tate the matrix invasive processes occurring after cartilage
calcification in a manner similar to that proposed for
MMPs during tumor invasion (MacDougall and Matri-
sian, 1995). On the other hand, the importance of MT1-
MMP for bone formation seems clear if we consider that1342 The Journal of Cell Biology | Volume 155, Number 7, 2001
mice deficient in this protease exhibit severe skeletal abnor-
malities that lead to the early death of these mutant ani-
mals (Holmbeck et al., 1999; Zhou et al., 2000). It has
been proposed that inadequate collagen turnover and de-
fects in angiogenesis underlie the observed phenotype, al-
though the possibility that impaired collagenase-3 activa-
tion could be responsible at least in part of the observed
phenotype cannot be ruled out. Nevertheless, and contrary
to the case of Cbfa1, MT1-MMP is not necessary for the
observed RA-induced expression of collagenase-3 during
bone formation as assessed by the presence of collagenase-3
transcripts in chondrocytes from metatarsal rudiments ob-
tained from MT1-MMP–null mice.
In this work, we have also analyzed the signaling path-
ways mediating the effect of RA on MMP expression in
chondrocytic cells. By using a series of specific inhibitors
for different signaling pathways, we have found that the
RA action on collagenase-3 is mediated by PKC and ty-
rosine kinase signal transduction pathways. The finding
that a specific PKC inhibitor is effective in blocking the
RA stimulatory process on collagenase-3 provides a func-
tional link between PKC and retinoid pathways, which are
generally considered to have antagonistic activities on dif-
ferent processes. On the other hand, the observation that
induction of collagenase-3 is also dependent on tyrosine
kinase activity agrees with previous findings, indicating
that these kinases play an essential role in signaling path-
ways regulating the proteolytic activity of diverse cells (Ra-
vanti et al., 1999b; Westermarck and Kähäri, 1999). Inter-
estingly, we have found that two different MAPK pathways
mediate opposite effects on collagenase-3 expression. In
fact, inhibition of the ERK1,2 pathway results in collage-
nase-3 induction, indicating that these MAPKs generate an
inhibitory rather than an activating signal on the produc-
tion of this protease. By contrast, inhibition of the p38
MAPK pathway extensively abolishes the RA stimulatory
effect on collagenase-3 expression. Similar results were ob-
tained in the analysis of the effect of both MAPK inhibi-
tors on Cbfa1 and osteocalcin expression. Therefore, it is
likely that the balance between p38 and ERK1,2 MAPK
pathways will finally determine if these genes are expressed
or not. Identification of p38 MAPK as an essential signal-
ing pathway in the induction of Cbfa1, osteocalcin, and
collagenase-3 suggests that this pathway might be impor-
tant during osteogenic differentiation processes. It is also
of interest that p38 MAPK has been proposed to play a
crucial role in the invasive phenotype of transformed kera-
tinocytes (Johansson et al., 2000). The finding that colla-
genase-3 expression is suppressed by p38 MAPK inhibitors
in bone-forming cells supports the proposal that this pro-
tease may facilitate some of the invasive processes that take
place during bone formation and remodeling.
A final consideration makes reference to the potential rele-
vance of the present results in the context of the therapeutic
use of retinoids in several pathological conditions (Lippman
et al., 1995). Retinoids have been proven to be effective in
treating hyperproliferative and inflammatory diseases, skin
pathologies, and cancer. Because it is generally accepted that
retinoids inhibit MMPs, it was anticipated that these en-
zymes, which play important roles in these pathologies,
could be efficiently targeted by retinoid-based treatments.
However, the finding that these compounds have a paradox-
ical effect on other MMPs like collagenase-3 and MT1-
MMP may represent a limitation for the therapeutic use of
retinoids in those pathological conditions, including malig-
nant tumors, with ability to produce these proteases. The
design and synthesis of novel dissociating retinoids, which
are devoid of transactivation properties (Chen et al., 1995),
could allow an efficient treatment of these diseases without
the undesired properties derived from the induction of fac-
tors such as MMPs.
Materials and methods
Materials
All media and supplements for cell culture were obtained from GIBCO
BRL. All-trans RA was from Sigma-Aldrich. Ro40-6055, Ro40-6973, Ro41-
5253, Ro46-5471, Ro48-2249, Ro44-4753, and Ro40-8757 were from F.
Hoffmann-La Roche Ltd. RXR-retinoid LG100064 was a gift from Dr. U.
Reichert (Galderma, Valbonne, France). TNF- , TPA, cycloheximide, stau-
rosporine, genistein, and indomethacin were from Sigma-Aldrich. H-89
was from Calbiochem.
DNA probes
The collagenase-3 probe was a 2.1-kbp fragment generated by RT-PCR
from mouse embryo RNA and corresponding to cDNA positions 334–2,473
(sequence data available from GenBank/EMBL/DDBJ under accession no.
X66473). The MT1-MMP probe was a 640-bp PCR fragment from positions
1,060–1,700 in the human cDNA sequence (sequence data available from
GenBank/EMBL/DDBJ under accession no. D26512). The gelatinase A
probe was a 2.8-kbp EcoRI fragment containing the full-length cDNA for
mouse gelatinase A (sequence data available from GenBank/EMBL/DDBJ
under accession no. M84324). Type II collagen probe was a 550-bp PstI
fragment cloned in PGEM 3Zf vector kindly provided by Dr. Y. Yamada
(National Institute of Dental and Craniofacial Research, Bethesda, MD).
Type X collagen probe was a 650-bp HindIII fragment of the mouse type X
collagen gene (Apte et al., 1992). Cbfa1 probe was a 1.7-kbp EcoRI frag-
ment from plasmid pCMV-Osf2/Cbfa1 (Ducy et al., 1997) kindly provided
by Dr. G. Karsenty (M.D. Anderson Cancer Center, Houston, TX). Osteocal-
cin probe was a 209-bp fragment generated by RT-PCR from mouse embryo
RNA and corresponding to cDNA positions 59–267 (sequence data avail-
able from GenBank/EMBL/DDBJ under accession no. X04142).
Embryonic metatarsal rudiment organ cultures
The three central metatarsal rudiments were isolated from 15.5-d-post-
coitum wild-type, Cbfa1
 / , and MT1-MMP
 /  mouse embryos. The
generation of Cbfa1 and MT1-MMP–deficient mice has been described
previously (Komori et al., 1997; Holmbeck et al., 1999). Isolated rudi-
ments were cultured in 1 ml of medium containing MEM (GIBCO BRL)
supplemented with 0.05 mg/ml ascorbic acid, 0.3 mg/ml L-glutamine,
0.05 mg/ml gentamicin, 1 mM glycerophosphate, and 0.2% BSA. Ex-
plants were grown at 37 C in a humidified 5% CO2 incubator. Retinoids
were added to cultures 12–14 h after dissection. Medium was changed
on the third day of culture. Metatarsal length was calculated at 24 h,
3 d, and 7 d of treatment by using a Nikon microscope equipped with a
micrometric eyepiece. Data are shown as the mean   SD. For statistical
analysis, data were compared among the different groups using a one-
way analysis of variance followed by Student-Newman t test. Metatarsal
rudiments were fixed overnight at 4 C in fresh 4% paraformaldehyde
and then processed according to two different protocols. Half of them
were dehydrated with a graded series of acetone and embedded in
Durkupan-ACM (Sigma-Aldrich). 1- m-thick sections were obtained on
a Reicher Ultracut E ultramicrotome and stained with toluidine blue for
structural studies and with von Kossa staining for mineralization. The re-
maining metatarsal rudiments were decalcified in 1 mM Tris, pH 7.5,
and 10% EDTA at 4 C for 2 h, dehydrated in ethanol, and embedded in
paraffin. 5- m-thick sections were used for cytochemical detection of
proteoglycans and for in situ hybridization.
Cell culture
Primary chondrocytes were isolated from ribs of newborn rats. Rib cages
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plemented with 10% FCS. They were incubated with 0.05 mg proteinase K
for 30 min at 37 C, washed, and treated with 1.5 mg collagenase (Type IA;
Sigma-Aldrich) for 3 h at 37 C. Chondrocytes were recovered by centrifu-
gation, filtered through a 150  m mesh, and plated onto Petri dishes. Cells
were maintained for 3–7 d in DME supplemented with insulin-transferrin-
selenium (Sigma-Aldrich) and thereafter treated with RA for 1–7 d in the
same medium also containing 0.05 mg/ml ascorbic acid, 0.3 mg/ml
L-glutamine, 0.05 mg/ml gentamicin, and 1 mM glycerophosphate. RCS
cells were provided by Dr. J.H. Kimura (Henry Ford Hospital, Detroit, MI).
Cells were maintained routinely in DME supplemented with 10% FCS and
100  g/ml gentamicin. To test the effect of retinoids, cells were plated and
allowed to adhere for 24 h in DME containing 10% FCS. Afterwards, the
serum concentration was reduced to 2%, and retinoids were added at dif-
ferent concentrations. Media were changed every 2 d.
Cytochemistry
Mineralization was detected by von Kossa staining. After fixation in 4%
paraformaldehyde in PBS for 30 min, cells were treated with 1% AgNO3
for 60 min at room temperature and fixed with 5% sodium hyposulfite.
Proteoglycan deposition in cell cultures was analyzed by Alcian blue
staining.
In situ hybridization
Experiments were basically performed as reported previously (Alvarez et
al., 2000). Hybridization with collagenase-3, Cbfa1, and osteocalcin
probes was performed at 58 C for 16 h in a humid chamber with 400 ng/
ml of DIG-labeled probe diluted in the same solution used for prehybrid-
ization. Parallel sections were hybridized with a labeled sense riboprobe
and used as negative controls.
Northern blot analysis
Cells were treated with retinoids or different agonists at the concentrations
and for the times indicated. Before RNA extraction, cells were pretreated
with 1 mg/ml hyaluronidase and 0.15 mg/ml trypsin-EDTA for 2 min at
room temperature. Total RNA isolated from the cells was separated by
electrophoresis in 1% agarose gels, blotted onto nylon membranes, and
hybridized as described previously (Jiménez et al., 1999).
Western blot analysis
Conditioned media were obtained after incubation of cells with the corre-
sponding agents. Proteins from conditioned media were precipitated in 5%
trichloroacetic acid, separated by SDS-PAGE, and transferred to nitrocellu-
lose membranes. For detection of collagenase-3, membranes were incu-
bated with a 1:5,000 dilution of monoclonal antibody 141-15A12 (Fuji
Chemicals), washed, and then incubated with a goat anti–mouse IgG anti-
sera conjugated to HRP. Finally, the membranes were washed and devel-
oped with an HRP chemiluminescence detection reagent (ECL system;
Amersham Pharmacia Biotech).
Determination of MAPK activation
Cells treated with the corresponding agonists were lysed in sample buffer
(62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 50 mM DTT, and
0.1% bromophenol blue), heated at 95 C for 10 min, fractionated in 10%
SDS-PAGE, and transferred to nylon membranes. Immunodetection of
JNK/stress-activated protein kinase, ERK 1,2, and p38 MAPK was per-
formed as described by the antibody supplier (New England Biolabs, Inc.)
and developed with the ECL system.
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